Robert A. Ingram
Mr. Robert Ingram, also known as Bob, is a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies. Prior to joining Hatteras, Mr. Ingram was Chief Executive Officer and Chairman of Glaxo/Wellcome. Mr. Ingram co-led the merger and integration that formed GlaxoSmithKline. Upon reaching mandatory retirement age of 60, Mr. Ingram served as the Vice Chairman, Pharmaceuticals at GSK before becoming Strategic Advisor to the CEO of GlaxoSmithKline Plc. Mr. Ingram serves as the Lead Director on the boards of Valeant Pharmaceuticals and Cree, Inc. He is also a member of the Board of Directors of Regeneron Pharmaceuticals, Inc. and is Chairman of Viamet, a private company focused on anti-infective research. In 2013, Bob received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors.
At the request of US President George H.W. Bush, Bob formed and chaired the CEO Roundtable on Cancer. In 2006, he was appointed by President George W. Bush to the National Institutes of Health, National Cancer Advisory Board. In 2014, Bob received the North Carolina Award, the highest civilian honor the state can bestow on an individual. He received the award for public service. He serves as Chairman of Research Triangle Foundation of North Carolina and Chairman of the GlaxoSmithKline Foundation.
Bob is a member of numerous other civic and professional organizations, including the Boards for the James B. Hunt Jr. Institute for Educational Leadership and Policy, H. Lee Moffitt Cancer Center, CEO Roundtable on Cancer, Research Triangle Institute and serves on the Advisory Board, Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California.
Bob graduated from Eastern Illinois University with a BS degree in Business Administration.